-
USMNT Coaching Search: Guardiola, Cherundolo, and Others Named as Pochettino Replacements
-
North Dakota Enacts Bipartisan Insulin Price Cap Amid National Push
-
Turkish Airlines Launches Fourth Mainland China Route to Chengdu
-
Basil Tuma Scores First Senior Goal as Malta Draws with Ten-Man Eswatini
-
RSC’s ‘Julius Caesar’ Reimagined in Women’s Prison Setting for School Tour
-
Rock & Roll Hall of Fame Inductees Announced; Attendance List Shrinks
-
Thomson Reuters Integrates CUBE Regulatory Intelligence into CoCounsel Legal
-
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
-
Does IRS Debt Expire? Clear Start Tax Explains the 10-Year Collection Statute and What Quietly Resets It
-
GameSquare's Hatchet Publishes TikTok Live for Gaming in H1 2026 Report
-
Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
-
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
-
Mako Mining Reports Q3 2026 Financial Results, Including Adjusted EBITDA(1) of US$30.3 million and EPS of US$0.19/share
-
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 13
-
How Families Plan and Save for Holiday Travel
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
Thousands of Urban Homes Left Without High-Speed Internet Due to Broadband Blackspots
-
General Hospital actor Randall England dies at 75
-
Bunnie XO artwork taken down from Jelly Roll’s Nashville bar
-
London museum removes Russell Brand hair exhibit after rape conviction
-
Arlington sentinel rebukes Pete Hegseth entourage for laughter near memorial
-
Yella Beezy sentenced to life for arranging rapper Mo3’s murder
-
Kylie Jenner employee describes closet ordeal and pepper-spray incident
-
Authorities to identify Montauk Mary and five other Long Island cold-case victims
-
Davante Adams injury deepens Los Angeles Rams receiver shortage
-
Barbie sequel negotiations stall over reported $25 million pay packages
-
João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
-
Bath & Body Works launches buy-one-get-one-free candle offer
-
Alberta Launches $5M Fund for Women’s Neurology Research to Address Gender Gaps
-
Itlu Arjuna receives U/A certificate ahead of theatrical release
IntraBio Appoints Dr. Marc C. Patterson, US Chief Medical Officer
AUSTIN, TX / ACCESS Newswire / January 17, 2025 / IntraBio Inc. proudly announces that Marc C. Patterson, MD, FRACP, FAAN, FANA, has joined the company as US Chief Medical Officer. Dr. Patterson brings decades of clinical and research expertise in rare and common neurodegenerative and neurodevelopmental diseases to IntraBio's leadership team, further driving the company's mission to develop and deliver innovative treatments for patients with these disorders.
Dr. Patterson joins IntraBio after a distinguished career at the Mayo Clinic in Rochester, Minnesota, where he served as a Professor of Neurology, Pediatrics, and Medical Genetics. His leadership roles at Mayo included Director of the Child Neurology Training Program and Chair of the Division of Child and Adolescent Neurology. Before his tenure at Mayo, he held prominent positions at Columbia University as Professor and Director of Pediatric Neurology and Director of the Child Neurology Training Program.
Dr. Patterson expressed his enthusiasm for this new role: "Joining IntraBio at this pivotal moment is an incredible opportunity. The company's groundbreaking pipeline of first-in-class compounds represents a new frontier in treating neurodegenerative and neurodevelopmental diseases. These therapies can transform lives for patients, families, and communities deeply impacted by these conditions. After dedicating my career to understanding and treating these disorders, I am eager to amplify that impact by advancing innovative solutions that could redefine the standard of care. With IntraBio, we are poised to make a profound difference for those who need it most."
About IntraBio
IntraBio Inc. is a global biopharmaceutical company that develops and commercializes targeted therapies for rare and common neurological and neurodevelopmental diseases. IntraBio's platform technologies result from decades of research and collaboration with universities and institutions worldwide, and leverages the expertise of its scientific founders from the University of Oxford and the University of Munich.
For more information about IntraBio, please visit the company's website at intrabio.com and follow IntraBio on X (@IntraBio) and LinkedIn (@IntraBio-Inc).
Contacts
Cass Fields
[email protected]
SOURCE: IntraBio Inc
View the original press release on ACCESS Newswire
F.Schneider--AMWN